Top Markets
Coin of the day
ImmunoGen, Inc. ImmunoGen, Inc.

ImmunoGen, Inc.

IMGN
Rang in Aktien #3091
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Aktienkurs
$31.23
Zuletzt synchronisiert: 2024-02-13
Marktkapitalisierung
$6.24B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel ImmunoGen, Inc. (IMGN)

Kategorie

Kursverlauf für ImmunoGen, Inc. (IMGN)
Höchster Schlusskurs: $30.21 am 2024-02-01

Niedrigster Schlusskurs: $8.89 am 1989-11-01
Kursverlauf der Aktie von ImmunoGen, Inc. von 1989 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 2.21%
2023 489.22%
2022 -28.32%
2021 5.29%
2020 49.08%
2019 -9.93%
2018 -22.03%
2017 260.54%
2016 -86.73%
2015 56.16%
2014 -42.60%
2013 17.48%
2012 6.39%
2011 30.28%
2010 10.33%
2009 104.59%
2008 -8.33%
2007 -18.87%
2006 1.39%
2005 -29.82%
2004 48.39%
2003 53.96%
2002 -80.05%
2001 -26.61%
2000 400.25%
1999 95.33%
1998 131.85%
1997 -63.52%
1996 56.47%
1995 -41.57%
1994 -68.18%
1993 -19.49%
1992 -35.88%
1991 67.74%
1990 29.68%
1989 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$549.78 42.00%
US
$1.05K 48.14%
NL
$146.07 490.64%
US
$121.62 -12.98%
AU
$764.47 6.25%
CH